Total Funding
40
5
Total FundingDebt Financing raised
Growth Score
-3 pts
Heat Score
-11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
1239094
Novadiol is a Kansas-based biopharmaceutical company that develops innovative medicines for people with kidney diseases.
- GP Georges: Founder & Chief Executive Officer
About the Company
Novadiol is a Kansas-based biopharmaceutical company that develops innovative medicines for people with kidney diseases. The company's late-stage candidate, Dendocrin, is focused on chronic kidney disease (CKD) patients with secondary hyperparathyroidism (SHPT). Unlike new chemical entities (NCE’s), Dendocrin has relatively low development
risk and low development costs. With a well-known safety and toxicity profile, Dendocrin is being re-positioned for the treatment of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) stages 3 and 4 patients.
Novadiol, Inc was founded in 2012 and Shawnee, KS, USA.
